larotrectinib
bayer
navigate phase 2 trial with larotrectinib. data from 34 patients with metastatic gi cancers and ntrk-fusions. orr: 33%. orr in mcrc patients (n19): 47%. mdor 7.3 m. mos 12.5 m (6.1 - 33.4 m) adverse events g1-2, well tolerated. #wcgic2022 
MD de la UN. Especialista en medicina interna, docencia y oncología.